Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-rhG-CSF prophylaxis in head and neck squamous cell carcinoma during concurrent chemoradiotherapy
ChiCTR2100048522Phase 4Not yet recruiting
- Sponsor
- Affiliated Hospital of North Sichuan Medical College
- Start
- Aug 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of pegfilgrastim in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Affiliated Hospital of North Sichuan Medical College. Primary endpoint: Peripheral blood cell count. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
pegfilgrastim
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2100048522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048522.